Relationship between Neuroleptic Extrapyramidal Syndromes and Patients’ All-Cause Mortality

Abstract

Introduction: It is important to understand factors contributing to a neuroleptic-related increased mortality risk. The objective of this study was to test whether the occurrence of neuroleptic-induced extrapyramidal syndromes (EPS) including tardive dyskinesia (TD) is associated with an increased patients’ all-cause mortality.

Methods: In 1995, a sample of 200 patients on neuroleptics was assessed with regard to the presence of Parkinson syndrome, akathisia, and TD. By 2003–2004, i.e., during the following 8–9 year period, 63 patients had died. Patients who had died were compared with 120 patients known to be still alive with regard to several socio-demographic variables and the presence of EPS at the first examination.

Results: At the basic assessment, there were no significant differences between patients later still alive and deceased patients with regard to TD. The deceased patients were more frequently women, older, suffered more frequently from an organic disorder, had higher average scores for Parkinson syndrome and less frequently akathisia. Multivariate analysis confirmed age as the only factor contributing to the group difference. Repeating the meta-analysis by Ballesteros et al. (2000) after inclusion of our data, TD remains a weak but a significant predictor of death (OR=1.4).

Discussion: Neuroleptic-induced EPS of parkinsonism, akathisia, and TD did not contribute to the patients’ all-cause mortality in this study. The association between TD and mortality merits further attention.

References

• 1 Ballesteros J, Gonzales-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies.  J Clin Psychopharmacol. 2000;  20 188-194
• 2 Barnes TRE. A rating scale for drug-induced akathisia.  Br J Psychiatry. 1989;  154 672-676
• 3 Benkert O, Hippius H. Compendium of Psychiatric Pharmacotherapy, 5th ed. Heidelberg: Springer 2005
• 4 Bennett DA, Beckett LA, Murray AM. et al . Prevalence of parkinsonian signs and associated mortality in a community population of older people.  N Engl J Med. 1996;  334 71-76
• 5 Byne W, Stamu C, Whjite L. et al . Prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia.  Int J Ger Psychiatry. 2000;  15 7-13
• 6 Casey DE, Rabins P. Tardive dyskinesia as a life-threatening illness.  Am J Psychiatry. 1978;  135 486-488
• 7 Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.  Am J Psychiatry. 2004;  161 414-425
• 8 Fahn S, Elton RL. and members of the UPDRS Development Committee .Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, eds. Recent Developments in Parkinson's Disease, vol.2 Florham Park NJ: Macmillan Health Care Information 1987: 153-164
• 9 Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Washington DC: United States Department of Health, Education and Welfare 1976: 534-537
• 10 Halliday J, Farrington S, MacDonald S. et al . Nithsdale schizophrenia surveys 23: Movement disorders.  Br J Psychiatry. 2002;  181 422-427
• 11 Inada T, Koshiishi M, Ohnishi K. et al . The life expectancy of schizophrenic patients with tardive dyskinesia.  Hum Psychopharmacol Clin Exp. 1992;  7 249-254
• 12 Jones PB, Barnes TRE, Davies L. et al . Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia.  Arch Gen Psychiatry. 2006;  63 1079-1087
• 13 Joukamaa M, Heliovaara M, Knekt P. et al . Schizophrenia, neuroleptic medication and mortality.  Br J Psychiatry. 2006;  188 122-127
• 14 Kane JM, Leucht S, Carpenter D. et al . , eds The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders.  J Clin Psychiatry. 2003;  64 ((12, Suppl)) 21-22
• 15 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
• 16 Kucharski LT, Smith JW, Dunn DD. Mortality and tardive dyskinesia [letter].  Am J Psychiatry. 1979;  136 1228
• 17 Leuner K, Müller WE. Dopamin in the prefrontal cortex and ist different modulation by conventional and atypical antipsychotics.  Pharmacopsychiatry. 2007;  40 ((Suppl.1)) S17-S26
• 18 Lieberman JA, Stroup TS, MacEvoy JP. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353 1209-1223
• 19 Markkula J, Helenius H, Lauerma H. On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population.  Nord J Psychiatry. 2007;  61 152-157
• 20 MacClelland HA, Dutta D, Metcalfe A. et al . Mortality and facial dyskinesia.  Br J Psychiatry. 1986;  148 310-316
• 21 Mehta D, Mallya A, Volavka J. Mortality of patients with tardive dyskinesia.  Am J Psychiatry. 1978;  135 371-372
• 22 Modestin J, Stephan PL, Erni T. et al . Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia.  Schizophr Res. 2000;  42 223-230
• 23 Modestin J, Vogt Wehrli M, Stephan PL. et al . Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.  Schizophr Res. 2008;  100 97-107
• 24 Montout C, Casadebalg F, Lagnaoui R. et al . Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients.  Schizophr Res. 2002;  57 147-156
• 25 Morens DM, Davis JW, Grandinetti A. et al . Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men.  Neurology. 1996;  46 1044-1050
• 26 Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.  Austr N Z J Psychiatry. 2004;  38 445-449
• 27 Schneeweiss S, Setoguchi S, Brookhart A. et al . Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.  Can Med Assoc J. 2007;  176 627-632
• 28 Schooler NR, Kane J. Research diagnoses for tardive dyskinesia.  Arch Gen Psychiatry. 1982;  39 486-487
• 29 Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment.  J Clin Psychopharmacol. 1983;  3 235-236
• 30 Tenback DE, Harten PN van, Slooff CJ. et al . Evidence that early extrapyramidal symptoms predict later tardive dyskinesa: a prospective analysis of 10 000 patients in the European Schizophrenia Outpatient Health Outomes (SOHO) Study.  Am J Psychiatry. 2006;  163 1438-1440
• 31 Harten PN Van, Matroos GE, Hoek HW. et al . The prevalence of tar-dive dystonia, tardive dyskinesa, parkinsonism and akathisia. The Curaçao Extrapyramidal Syndromes Study I.  Schizophr Res. 1996;  19 195-203
• 32 Wirshing WC. Movement disorders associated with neuroleptic treatment.  J Clin Psychiatry. 2001;  62 ((Suppl. 21)) 15-18
• 33 Yagi G, Takamiya M, Kanba S. et al . Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study.  Keio J Med. 1989;  38 70-72
• 34 Yassa R, Mohelsky H, Dimitry R. et al . Mortality rate in tardive dyskinesia.  Am J Psychiatry. 1984;  141 1018-1019
• 35 Yassa R, Jones BD. Complications of tardive dyskinesia: a review.  Psychosomatics. 1985;  26 305-313
• 36 Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia.  Acta Psychiatr Scand. 1987;  75 74-77

Correspondence